VanEck Morningstar Wide Moat Value ETF(MVAL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
VanEck Morningstar Wide Moat Value ETF
MVAL.US
News
View More

Kimberly-Clark Files Registration Statement for Merger with Kenvue

Kimberly-Clark Corporation has announced a merger with Kenvue Inc., making Kenvue a wholly owned subsidiary. The merger will occur in two steps, with the SEC declaring the registration statement effective on December 16, 2025. A joint proxy statement/prospectus has been filed, but stockholders have initiated legal actions claiming insufficient disclosures regarding the deal.

Reuters·
US
KVUE
-0.35%
US
KMB
-1.09%
Reuters·
US
KVUE
-0.35%
US
KMB
-1.09%

Is Danaher Corp Gaining or Losing Market Support?

Danaher Corp's short interest has decreased by 4.35%, with 8.29 million shares sold short, representing 1.32% of available shares. It would take an average of 3.19 days for traders to cover their short positions. A decline in short interest may indicate a more bullish market sentiment towards the stock. Compared to its peers, Danaher Corp has a lower short interest percentage of 7.36%.

benzinga_article·
US
DHR
-1.63%
benzinga_article·
US
DHR
-1.63%

REG - Air Astana JSC - Results of Extraordinary GM of Shareholders

Air Astana JSC held an Extraordinary General Meeting on January 15, 2026, where shareholders approved a major transaction with The Boeing Company to acquire five Boeing 787-9 aircraft. This acquisition represents over 50% of the company's total asset value, with deliveries scheduled between 2032 and 2035. The CEO is authorized to take necessary actions to implement this decision. Air Astana is the largest airline group in Central Asia and the Caucasus, operating a fleet of 62 aircraft and recognized for its service quality.

London Stock Exchange·
US
BA
-0.02%
London Stock Exchange·
US
BA
-0.02%

BMS reports positive results in Phase III SCOUT-HCM trial for oHCM

Bristol Myers Squibb (BMS) has reported positive results from the Phase III SCOUT-HCM trial for Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents aged 12 to under 18. The trial met its primary endpoint, showing significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared to placebo. Safety data remained consistent with adult profiles, and BMS plans to present comprehensive results at a medical congress. The study continues with active treatment and long-term extension phases.

WorldPharmaceuticals·
US
BMY
-2.40%
WorldPharmaceuticals·
US
BMY
-2.40%

BUZZ-Street View: Merck signals renewed confidence in growth after Keytruda patent loss

Merck has raised its revenue outlook to $70 billion by the mid-2030s, signaling renewed confidence despite the impending loss of its Keytruda patent, which could impact 50% of its revenue. Analysts from Bernstein, BMO Capital Markets, and Citi provided mixed reviews, with Bernstein highlighting the challenges ahead, while BMO noted a newfound confidence in Merck's strategy. Citi acknowledged progress but cautioned that Merck is not yet fully secure against the patent loss's effects.

Reuters·
US
MRK
-1.93%
Reuters·
US
MRK
-1.93%
© 2026 Longbridge｜Disclaimer